Mazdutide 10vials/box

Product Basic Information

Full Name: Mazdutide (Development Code IBI362, LY3305677)

Essence: A GLP-1R/GCGR dual receptor agonist, a synthetic peptide analog of mammalian oxyntomodulin (OXM)

Form: Sterile lyophilized peptide powder, individually packaged in vials

Uses: In vitro research reagents related to metabolic syndrome, obesity, type 2 diabetes, and non-alcoholic fatty liver disease (MASLD)

II. Mechanism of Action

Mazdutide has a dual-target synergistic effect, achieving dual metabolic regulation of "inhibiting intake + increasing consumption" by balancing the activation of GLP-1 receptor (GLP-1R) and glucagon receptor (GCGR):

GLP-1R Pathway ("Blocking"): Acts on the central nervous system and gastrointestinal tract, inhibiting appetite, delaying gastric emptying, and reducing food intake; simultaneously promoting pancreatic glucose-dependent insulin secretion, lowering blood glucose.

GCGR Pathway (“Breakthrough”): Targets the liver and brown adipose tissue, increasing basal metabolic rate, promoting lipid oxidation and decomposition, and reducing hepatic lipid deposition, overcoming the limitation of single GLP-1 agonist-based weight loss relying solely on “eating less”.

Molecular Characteristics: Modified with fatty acid side chains, resulting in a significantly prolonged half-life, suitable for long-acting research models with weekly dosing.

III. Core Research Efficacy

Powerful Weight Loss: In in vitro models, it synergistically inhibits food intake and increases energy expenditure, significantly reducing weight, waist circumference, and body fat percentage, superior to single GLP-1 agonist controls.

Glucose Regulation: Promotes insulin secretion, improves insulin sensitivity, and reduces glycated hemoglobin (HbA1c), suitable for research on the mechanisms of type 2 diabetes.

Liver Protection: Reduces hepatic fat accumulation, lowers transaminase levels, improves pathological indicators of non-alcoholic fatty liver disease (MASLD), and inhibits intrahepatic inflammation and endoplasmic reticulum stress.

Comprehensive Metabolic Improvement: Reduces blood lipids, uric acid, and blood pressure, improves multiple cardiovascular metabolic risk factors, suitable for comprehensive intervention research on metabolic syndrome.

Long-acting model adaptation: Supports weekly dosing in vitro/animal long-acting dosing regimens, simplifying experimental design and operation.

IV. Reconstitution and Storage Specifications

Reconstitution solvent: Sterile water for injection, 0.6% acetic acid aqueous solution for preparing the experimental working solution.

Storage requirements: Unopened lyophilized powder: Store at 2-8℃, protected from light, sealed, and refrigerated. Keep away from moisture and high temperatures. Freezing is strictly prohibited.

Reconstituted liquid: Refrigerate at 4℃, protected from light.